How certain DNA repair genes affect radiation therapy in prostate cancer
Synergistic DNA repair genes and sensitivity to radiation therapy in prostate cancer
This study is looking at how a gene called FAM35A affects how prostate cancer cells react to radiation therapy, especially in cases where the cancer doesn't respond to regular treatments, with the goal of finding better ways to help patients with advanced prostate cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-10291608 on NIH RePORTER |
What this research studies
This research investigates the role of a specific DNA repair gene, FAM35A, in how prostate cancer cells respond to radiation therapy. It aims to understand the mechanisms by which FAM35A influences treatment resistance and sensitivity in prostate cancer, particularly in cases that have become resistant to standard therapies. The study will utilize biochemical and cell biology techniques to explore how FAM35A interacts with other proteins involved in DNA repair, potentially leading to improved treatment strategies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic prostate cancer or metastatic castration-resistant prostate cancer who are undergoing or considering radiation therapy.
Not a fit: Patients with early-stage prostate cancer or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation therapies for prostate cancer patients, particularly those with treatment-resistant forms of the disease.
How similar studies have performed: Previous research has shown promising results in understanding DNA repair mechanisms in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Charlotte, United States
- University of North Carolina Charlotte — Charlotte, United States (Active)
Researchers
- Principal investigator: Tomida, Junya — University of North Carolina Charlotte
- Study coordinator: Tomida, Junya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.